Skip to main content
Back to Trials
NCT07814079Recruiting

Targeted Ablation to Isolate Scar Channels Causing Ventricular Tachycardia

New York Medical College

Start Date

3/27/2025

Completion Date

12/9/2028

Summary

The goal of this study is to map conducting channels within scar that cause ventricular tachycardia (VT) in patients with scar in their hearts in order to block these channels from causing VT with targeted radiofrequency ablation (cautery). Participants undergoing VT ablation mapping of these channels by pacing many sites within the scar area and determining where these channels exit the scar into normal tissue. These exits will be ablated. Immediate success and success at 1 year will be evaluated.

Detailed Description

After standard VT induction and mapping procedures (noninvasive identification of induced VT exit sites with Vektor vMap; substrate mapping; initial pacemapping), the study will consist of pacing within the substrate and mapping all channel exits both noninvasively with vMap as well as invasively with high density mapping catheters within the heart by escape mapping (all paced sites creating a consistent paced morphology, up to the shortest stimulus-to-QRS interval achieved) as well as focal activation mapping of this channel exit while pacing within the channel. The noninvasive map will aid in focusing invasive mapping to a small area of the substrate. Once the exit sites are determined, ablation energy will be delivered based on the mapped exit sites in the substrate channel within 0.5cm of the exit with the goal of blocking each exit site mapped. After the ablation lesion set is delivered, repeat attempt to induce VT will be performed. If more VT is induced, additional ablation energy will be delivered guided by standard mapping techniques (substrate, slow conduction zones, pacemapping).

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Patients with structural heart disease undergoing VT ablation Exclusion Criteria: 1. Unable or unwilling to sign consent 2. Cardiogenic shock or NYHA Class IV heart failure and not a candidate for mechanical circulatory support for the procedure (percutaneous left ventricular assist device (LVAD), extracorporeal membrane oxygenation, or implanted LVAD) 3. Absence of substrate during initial voltage mapping

Interventions

PROCEDURE

Selective Substrate Isolation

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Ventricular Tachycardia (VT)Ischemic CardiomyopathyNonischemic Cardiomyopathy

Locations

Westchester Medical Center

Valhalla, New York 10595

United States